Tepurenone trial for HSCT

Development of immunosuppressive therapy with teprenone to reduce the severity of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061210072

Enrollment

Registered

2022-01-27

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological disease

Interventions

Treated group: In addition to the conventional treatment, 50 mg of teprenone is administered after each meal for three weeks. Non-treated group: Conventional treatment only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Allogeneic hematopoietic stem cell transplant recipients

Exclusion criteria

Exclusion criteria: (1) Under 15 years old (2) With mental illness or psychiatric symptoms (3) Pregnancy, lactation (4) Severe allergy to teprenone

Design outcomes

Primary

Measure	Time frame
Incidence of severe acute GVHD (Grade III or higher of acute GVHD)	—

Secondary

Measure	Time frame
1) Survival rate at 100 days after transplantation 2) Factors that enable early prediction of acute GVHD severity. 3) Teprenone-induced changes in oxidative stress markers, including Trx-1 and HSP-70, and expression of pro-inflammatory cytokines	—

Contacts

Public ContactKeiko Fujii

Okayama University Hospital

keikofujii@okayama-u.ac.jp+81-862357768

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026